Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3883 - Phase III randomized, double-blind, controlled studies of the PI3K inhibitor copanlisib in combination with rituximab or rituximab-based chemotherapy in subjects with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL): CHRONOS-3 and CHRONOS-4

Date

09 Sep 2017

Session

Poster display session

Presenters

John Gerecitano

Citation

Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373

Authors

J. Gerecitano1, H. Zheng2, L. Mongay Soler2, R. Ito3, D. Reis4, C. Lu5, J. Shen5, B.H. Childs2, P.L. Zinzani6

Author affiliations

  • 1 Lymphoma Service/developmental Therapeutics Clinic, Department Of Medicine, Memorial Sloan-Kettering Cancer Center, 10021 - New York/US
  • 2 Clinical Development, Bayer HealthCare Pharmaceuticals Inc., 07981 - Whippany/US
  • 3 Development Operations, Bayer HealthCare Pharmaceuticals Inc., 07981 - Whippany/US
  • 4 Development Operations, Bayer SA, São Paulo/BR
  • 5 Clinical Statistics, Bayer HealthCare Pharmaceuticals Inc., 07981 - Whippany/US
  • 6 Institute Of Hematology “l. E A. Seràgnoli”, University of Bologna, Bologna/IT
More

Resources

Abstract 3883

Background

Copanlisib is a pan-Class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against PI3K-α and PI3K-δ isoforms. Recently, the CHRONOS-1 study demonstrated efficacy of copanlisib monotherapy in patients with relapsed or refractory iNHL with an acceptable safety profile (Dreyling et al., AACR 2017). Two randomized phase III studies are ongoing to evaluate the efficacy and safety of copanlisib in combination with standard therapy: Rituximab [R] either alone or in combination with chemotherapy including an alkylating agent (e.g. bendamustine [R-B] or CHOP [R-CHOP]) in ≥ 2nd line iNHL patients who are relapsed but non-refractory to R or R-based chemotherapy.

Trial design

Both studies include iNHL patients (including follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, or lymphoplasmacytic lymphoma/Waldenström macroglobulinemia) who have relapsed but are non-refractory after at least 1 prior line of therapy including R. The primary efficacy variable is progression-free survival. In CHRONOS-3, 567 patients unfit/unwilling to receive chemotherapy or who have progressed or relapsed ≥12 months after the last R-based regimen will be randomized 2:1 to copanlisib (60 mg) or placebo administered intravenously on days 1, 8 and 15 of a 28-day cycle until progression in combination with 375 mg/m2 of R days 1, 8, 15 and 22 followed by R bi-monthly up to cycle 9. For CHRONOS-4, a safety run-in phase will be conducted with 45 mg and 60 mg copanlisib with R-B or R-CHOP. Copanlisib will be admnistered (as above) with either B iv 90 mg/m2 days 1 and 2 each 28 days, or on days 1 and 8 of a 21-day cycle with CHOP per standard dosing. After the run-in phase, 520 patients eligible to receive R-B or R-CHOP will be randomized 1:1 to either copanlisib or placebo and receive up to 6 cycles followed by copanlisib or placebo monotherapy. Safety run-in of RB plus copanlisib was assessed by the Data Monitoring Committee and 60 mg was deemed as the copanlisib phase III dose (Gerecitano et al. ICML 2017). The phase III portion of the trial with copanlisib/placebo plus RB is ongoing.

Clinical trial identification

NCT02367040; NCT02626455

Legal entity responsible for the study

Bayer AG

Funding

Bayer AG

Disclosure

H. Zheng, R. Ito, C. Lu, J. Shen, B.H. Childs, L. Mongay Soler: Employment: Bayer HealthCare Pharmaceuticals Inc. D. Reis: Employment: Bayer SA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.